TY - JOUR T1 - Waldenström's macroglobulinemia: A clinical perspective in the era of novel therapeutics JF - Annals of Oncology Y1 - 2016 A1 - Dimopoulos, M.A. A1 - Kastritis, E. A1 - Ghobrial, I.M. KW - Efficacy KW - novel agents KW - safety KW - Treatment guidelines KW - Waldenström's macroglobulinemia AB - Waldenström's macroglobulinemia (WM) is a rare, low-grade malignancy with no established standard of care. Rituximab regimens are most commonly used, supported by their efficacy in hematologic malignancies, including WM. A growing number of investigational regimens for WM have been evaluated in phase II clinical trials, including single-agent and combination strategies that include newer-generation monoclonal antibodies (ofatumumab and alemtuzumab), proteasome inhibitors (bortezomib and carfilzomib), immunomodulatory agents (thalidomide and lenalidomide), phosphoinositide 3-kinase/protein kinase B (Akt)/mammalian target of rapamycin pathway inhibitors (everolimus and perifosene), a Bruton's tyrosine kinase inhibitor (ibrutinib), and a histone deacetylase inhibitor (panobinostat). Other novel agents are in early-stage development for WM. International treatment guidelines for WM suggest suitable regimens in the newly diagnosed and relapsed/refractory settings, in accordance with patient age, disease presentation, and efficacy and safety profiles of particular drugs. These factors must be considered when choosing appropriate therapy for individual patients with WM, to maximize response and prolong survival, while minimizing the risk of adverse events. This review article provides a clinical perspective of the modern management of patients with WM, in the context of available trial data for novel regimens and recently updated treatment guidelines. © The Author 2015. VL - 27 UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84961675603&doi=10.1093%2fannonc%2fmdv572&partnerID=40&md5=8b2e53e61d481c2b1b742cd8ef405a5f IS - 2 N1 - Cited By :2Export Date: 21 February 2017 ER -